Patents by Inventor Ronald S. Vladyka
Ronald S. Vladyka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230165799Abstract: A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.Type: ApplicationFiled: December 5, 2022Publication date: June 1, 2023Applicants: R.P. Scherer Technologies, LLC, UNIVERSITY OF MISSISSIPPIInventors: Sampada Bhaskar UPADHYE, Ronald S. VLADYKA, Michael Andrew REPKA, Jun-Bom PARK, Roshan Vijay TIWARI, Hemlata Gunga PATIL, Joseph Thomas MOROTT, JR., Wenli LU
-
Patent number: 11660267Abstract: Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.Type: GrantFiled: November 17, 2015Date of Patent: May 30, 2023Assignee: Biohaven Therapeutics Ltd.Inventors: Vladimir Coric, Robert Berman, Ronald S. Vladyka, Amgad Saleh, Danny Yu
-
Patent number: 11529313Abstract: A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.Type: GrantFiled: July 22, 2020Date of Patent: December 20, 2022Assignees: R.P. Scherer Technologies, LLC, UNIVERSITY OF MISSISSIPPIInventors: Sampada Bhaskar Upadhye, Ronald S. Vladyka, Michael Andrew Repka, Jun-Bom Park, Roshan Vijay Tiwari, Hemlata Gunga Patil, Joseph Thomas Morott, Jr., Wenli Lu
-
Patent number: 11253501Abstract: Embodiments described herein are directed to novel pharmaceutical compositions comprising a plurality of microgranules comprising nitroimidazole compounds, and uses of these pharmaceutical compositions in the treatment of bacterial vaginosis.Type: GrantFiled: June 1, 2016Date of Patent: February 22, 2022Assignee: LUPIN INC.Inventors: David Palling, Ronald S. Vladyka, Joseph Amprey
-
Publication number: 20210038499Abstract: Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.Type: ApplicationFiled: October 25, 2020Publication date: February 11, 2021Inventors: Vladimir Coric, Robert Berman, Ronald S. Vladyka, Amgad Saleh, Danny Yu
-
Publication number: 20200345643Abstract: A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.Type: ApplicationFiled: July 22, 2020Publication date: November 5, 2020Applicants: R.P. Scherer Technologies, LLC, UNIVERSITY OF MISSISSIPPIInventors: Sampada Bhaskar Upadhye, Ronald S. Vladyka, Michael Andrew Repka, Jun-Bom Park, Roshan Vijay Tiwari, Hemlata Gunga Patil, Joseph Thomas Morott, JR., Wenli Lu
-
Patent number: 10786459Abstract: A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.Type: GrantFiled: April 21, 2017Date of Patent: September 29, 2020Assignees: R. P. Scherer Technologies LLC, University of MississippiInventors: Sampada Bhaskar Upadhye, Ronald S. Vladyka, R.ph, Michael Andrew Repka, Jun-Bom Park, Roshan Vijay Tiwari, Hemlata Gunga Patil, Joseph Thomas Morott, Jr., Wenli Lu
-
Publication number: 20180153794Abstract: Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.Type: ApplicationFiled: November 17, 2015Publication date: June 7, 2018Inventors: Vladimir Coric, Robert Berman, Ronald S. Vladyka, Amgad Saleh, Danny Yu
-
Publication number: 20170319486Abstract: A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.Type: ApplicationFiled: April 21, 2017Publication date: November 9, 2017Applicants: CATALENT PHARMA SOLUTIONS INC., UNIVERSITY OF MISSISSIPPIInventors: Sampada Bhaskar UPADHYE, Ronald S. VLADYKA, R.ph, Michael Andrew REPKA, Jun-Bom PARK, Roshan Vijay TIWARI, Hemlata Gunga PATIL, Joseph Thomas MOROTT, JR., Wenli LU
-
Publication number: 20160354348Abstract: Pharmaceutical formulations comprise sustained-release zonisamide. Methods of preparing such pharmaceutical formulations involve intermixing zonisamide with a suitable excipient configured to control the dissolution profile of the zonisamide. Methods of treatment involve administering the pharmaceutical formulations to patients in need of such treatment.Type: ApplicationFiled: January 22, 2016Publication date: December 8, 2016Inventors: Anthony A. McKinney, Gary Tollefson, Simon Kwok-Pan Yau, Ronald S. Vladyka, Rick Soltero
-
Publication number: 20160346252Abstract: Embodiments described herein are directed to novel pharmaceutical compositions comprising a plurality of microgranules comprising nitroimidazole compounds, and uses of these pharmaceutical compositions in the treatment of bacterial vaginosis.Type: ApplicationFiled: June 1, 2016Publication date: December 1, 2016Applicant: SYMBIOMIX THERAPEUTICS, LLCInventors: David PALLING, Ronald S. VLADYKA, Joseph AMPREY
-
Publication number: 20140080857Abstract: Pharmaceutical formulations comprise sustained-release zonisamide. Methods of preparing such pharmaceutical formulations involve intermixing zonisamide with a suitable excipient configured to control the dissolution profile of the zonisamide. Methods of treatment involve administering the pharmaceutical formulations to patients in need of such treatment.Type: ApplicationFiled: August 13, 2013Publication date: March 20, 2014Applicant: Orexigen Therapeutics, Inc.Inventors: Anthony A. McKinney, Gary Tollefson, Simon Kwok-Pan Yau, Ronald S. Vladyka, Rick Soltero
-
Patent number: 8496967Abstract: A solid pharmaceutical composition containing AP23573 suitable for oral administration is disclosed.Type: GrantFiled: December 23, 2009Date of Patent: July 30, 2013Assignee: ARIAD Pharmaceuticals, Inc.Inventors: Ronald S. Vladyka, Jr., David C. Dalgarno, John D. Iuliucci
-
Publication number: 20100247643Abstract: A solid pharmaceutical composition containing AP23573 suitable for oral administration is disclosed.Type: ApplicationFiled: December 23, 2009Publication date: September 30, 2010Applicant: ARIAD Pharmaceuticals, Inc.Inventors: Ronald S. Vladyka, JR., David C. Dalgarno, John D. Iuliucci
-
Publication number: 20080161335Abstract: A solid pharmaceutical composition containing AP23573 suitable for oral administration is disclosed.Type: ApplicationFiled: November 14, 2007Publication date: July 3, 2008Inventors: Ronald S. Vladyka, David C. Dalgarno, John D. Iuliucci
-
Patent number: 6858725Abstract: Granulation of microcrystalline cellulose with a granulating fluid consisting of water and a water-miscible, volatile, polar organic solvent yields porous granules which are comprised of particles that are larger than the ungranulated microcrystalline cellulose. This granulated microcrystalline cellulose is capable of cushioning controlled release particles and barrier coated particles from the compression forces used in tableting, thereby maintaining the physical integrity of the components of the tablet.Type: GrantFiled: November 9, 2000Date of Patent: February 22, 2005Assignee: R.P. Scherer Technologies, Inc.Inventors: Ronald S. Vladyka, Jr., David F. Erkoboni, Christopher A. Sweriduk
-
Publication number: 20040081701Abstract: The present invention provides a method for preparing a spray-dried, compressible granular formulation for preparing pharmaceutical tablets in which essentially water-insoluble, acidic, amphoteric, and basic pharmaceutically active agents are converted to more water-soluble salts which are granulated with hydrolyzed cellulose, drug-containing slurries, the resulting granulations, capsules containing granulations, and pharmaceutical tablets compressed from such granules. In these formulations there is employed from 1% to 85% by weight of the pharmaceutically active agent in its salt form, from 5% to 99% of hydrolyzed cellulose, based on the dry weight of the granulation, and optionally, conventional granulation and/or tableting additives such as surfactants, disintegrants, and antiadherents/flow aids. Said tablets have significantly increased dissolution of the pharmaceutically active agent at the pH of the gastrointestinal tract in comparison with the unconverted free pharmaceutically active agent.Type: ApplicationFiled: June 9, 2003Publication date: April 29, 2004Inventors: David F. Erkoboni, Ronald S. Vladyka, Christopher A. Sweriduk, Andrew J. Favara
-
Patent number: 6596312Abstract: The present invention provides a method for preparing a spray-dried, compressible granular formulation for preparing pharmaceutical tablets in which essentially water-insoluble, acidic, amphoteric, and basic pharmaceutically active agents are converted to more water-soluble salts which are granulated with hydrolyzed cellulose, drug-containing slurries, the resulting granulations, capsules containing granulations, and pharmaceutical tablets compressed from such granules. In these formulations there is employed from 1% to 85% by weight of the pharmaceutically active agent and its salt form, from 5% to 99% of hydrolyzed cellulose, based on the dry weight of the granulation, and optionally, conventional granulation and/or tableting additives such as surfactants, disintegrants, and antiadherents/flow aids. Said tablets have significantly increased dissolution of the pharmaceutically active agent at the pH of the gastrointestinal tract in comparison with the unconverted free pharmaceutically active agent.Type: GrantFiled: September 26, 2000Date of Patent: July 22, 2003Assignee: R.P. Scherer Technologies, Inc.Inventors: David F. Erkoboni, Ronald S. Vladyka, Jr., Christopher A. Sweriduk, Andrew J. Favara
-
Patent number: 6511681Abstract: A formulation of a sparingly water-soluble, crystalline pharmaceutically active agent wherein the active agent is converted to and stabilized in its amorphous form as a solid solution of a normally hydrophobic vehicle is described. The amorphous state is stabilized by the composition of the formulation, providing long shelf life of the improved composition. This stabilized formulation also provides increased solubility and bioavailability of the active agent. Solutions of the active agent are stabilized by the composition, preventing recrystallization and precipitation of the less soluble, crystalline form of the active agent from aqueous solutions thereof.Type: GrantFiled: June 21, 2001Date of Patent: January 28, 2003Assignee: R.P. Scherer Technologies, Inc.Inventors: Ronald S. Vladyka, Jr., David F. Erkoboni, Pamela R. Stergios
-
Patent number: 6497905Abstract: A formulation of a sparingly water-soluble, crystalline pharmaceutically active agent wherein the active agent is converted to and stabilized in its amorphous form as a solid solution of a normally hydrophobic vehicle is described. The amorphous state is stabilized by the composition of the formulation, providing long shelf life of the improved composition. This stabilized formulation also provides increased solubility and bioavailability of the active agent. Solutions of the active agent are stabilized by the composition, preventing recrystallization and precipitation of the less soluble, crystalline form of the active agent from aqueous solutions thereof.Type: GrantFiled: March 20, 2000Date of Patent: December 24, 2002Assignee: R.P. Scherer Technologies, Inc.Inventors: Ronald S. Vladyka, Jr., David F. Erkoboni, Pamela R. Stergios